![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Pharmaceutical Sciences, University of Salerno, Fisciano (Salerno), Italy
The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the ability of the clinicians to manage obesity. Large-scale clinical trials have demonstrated that rimonabant therapy can reduce obesity. Although, the precise mechanisms of action of rimonabant have to be further dissected, it is emerging, from both preclinical and clinical research, that not only is rimonabant an antiobesity drug, but also its pleiotropic functions affect a broad range of diseases, from obesity-related comorbidities to drug dependence and cancer. Here we review recent data from the literature and discuss the full pharmacological potential of this drug.
Received for publication November 29, 2006.
Accepted for publication February 27, 2007.
Address correspondence to: Prof. Maurizio Bifulco, Department of Pharmaceutical Sciences, University of Salerno, Via Ponte don Melillo, 84084 Fisciano, Salerno, Italy. E-mail: maubiful{at}unisa.It
This article has been cited by other articles:
|
|
 |
|
  R. Cinar and M. Szucs CB1 Receptor-Independent Actions of SR141716 on G-Protein Signaling: Coapplication with the {micro}-Opioid Agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol Unmasks Novel, Pertussis Toxin-Insensitive Opioid Signaling in {micro}-Opioid Receptor-Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 567 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, S. L. Lee, and R. A. Peterfreund New Therapeutic Agents for Diabetes Mellitus: Implications for Anesthetic Management Anesth. Analg., June 1, 2009; 108(6): 1803 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Esposito, M. C. Proto, P. Gazzerro, C. Laezza, C. Miele, A. T. Alberobello, V. D'Esposito, F. Beguinot, P. Formisano, and M. Bifulco The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase Mol. Pharmacol., December 1, 2008; 74(6): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza Endocannabinoids in endocrine and related tumours Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Simon and B. F. Cravatt Anandamide Biosynthesis Catalyzed by the Phosphodiesterase GDE1 and Detection of Glycerophospho-N-acyl Ethanolamine Precursors in Mouse Brain J. Biol. Chem., April 4, 2008; 283(14): 9341 - 9349. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
